research Medical management of benign prostatic hyperplasia
Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
Search
for
Sort by
Research
90-120 / 698 results 
research Anti-androgenic effect of sesquiterpenes isolated from the rhizomes of Curcuma aeruginosa Roxb.
Germacrone from Curcuma aeruginosa may help treat conditions related to male hormones by blocking a specific enzyme.
research 5α‐reductase inhibitors: Evaluation of their potential confounding effect on GC‐C‐IRMS doping analysis
5α-reductase inhibitors can interfere with doping tests by masking banned substances.
research Hormone therapy in acne
Hormonal treatment is effective for women with acne not helped by usual treatments, especially if they have hormonal imbalances.
research Endocrine treatment of benign prostatichypertrophy: Current concepts
New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.
research Androgenetic alopecia: An autosomal dominant disorder
Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.
research Urinary steroids in women with androgenic alopecia
Women with hair loss had higher levels of certain hormones, suggesting a link to a condition like PCOS.
research Dihydrotestosterone Stimulates 5a-Reductase Activity in Pubic Skin Fibroblasts*
Dihydrotestosterone increases the activity of an enzyme in pubic skin cells that converts testosterone to dihydrotestosterone.
research Trace elements content and hormonal profiles in women with androgenetic alopecia
Women with AGA have more androstenedione and dihydrotestosterone, less copper and zinc; copper imbalance affects AGA; treatment improves hormones and minerals.
research Cytostatics and immunosuppressive drugs
Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.
research Mechanistic synergy of hair growth promotion by the Avicennia marina extract and its active constituent (avicequinone C) in dermal papilla cells isolated from androgenic alopecia patients
Avicennia marina extract and avicequinone C can potentially promote hair growth and treat hair loss by interfering with hair loss mechanisms and boosting growth factors.
research 5α‐Reductase inhibitors and prostatic disease
5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
research Analytical methods of dutasteride: An overview
Dutasteride is more effective than finasteride for hair loss treatment.
research Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
research Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies
Obesity worsens PCOS symptoms, and PCOS may lead to more weight gain; managing both requires a holistic approach that includes mental health.
research Expression of mRNA for androgen receptor, 5alpha-reductase and 17beta-hydroxysteroid dehydrogenase in human dermal papilla cells
Hair sensitivity to androgens is partly controlled by specific enzyme expressions in different hair areas.
research Finasteride para disminuir el sangrado en resección transuretral de próstata en pacientes con sonda Foley
Finasteride reduces bleeding during prostate surgery.
research Androgenetische Alopezie beim Mann . Male androgenetic alopecia
Male androgenetic alopecia involves hair follicle miniaturization due to DHT, with potential treatments using inhibitors and blockers.
research Novel agents for the treatment of alopecia
New treatments for hair loss show promise, especially finasteride for men and a stronger minoxidil formula.
research Natural Product-Inspired Bis(trifluoromethyl) Phenyl Hydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitors of Human Steroid 5α-Reductase Type-1: Synthesis, In Vitro, and In Silico Studies
New compounds show promise as nonsteroidal treatments for hair loss.
research Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women
A 5 mg dose of transdermal testosterone cream effectively restores testosterone levels in postmenopausal women.
research Connarus semidecandrus Jack Exerts Anti-Alopecia Effects by Targeting 5α-Reductase Activity and an Intrinsic Apoptotic Pathway
Connarus semidecandrus Jack extract promotes hair growth and thickness, reduces prostate cancer cell growth, and could potentially be used as a treatment for hair loss.
research A Convenient Synthesis of (16S,20S)-3β-Hydroxy-5α-pregnane-20,16-carbolactam and Its N-alkyl Derivatives
A new, efficient method was developed to synthesize a specific compound and its derivatives.
research Synthesis and Actions of 5α-Reduced Metabolites of Testosterone in the Nervous System
Testosterone and its metabolites affect brain functions and could help treat neurological disorders.
research Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
Compound 4 is a promising treatment for hair loss with low toxicity.
research Adverse effects of the 5-alpha-reductase inhibitor finasteride on Daphnia magna: Endocrine system and lipid metabolism disruption
Finasteride harms Daphnia magna's reproduction, growth, and metabolism.
research Optimal concentration selection of active pharmaceutical ingredients in the cream-mask intended for androgenic alopecia treatment according to experimental results on paramecium caudatum biological model
The best mix for a hair loss treatment cream is 10% Sophora japonica tincture and 5% Serenoa repens extract.
research In-vivo uptake and metabolism of testosterone by the skin and other tissues of the rat
Rat skin takes up and processes testosterone differently than other organs, with testosterone being more important for the skin than its metabolite 5α-DHT.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.